Journal profile · Medicine, Research & Experimental
In Vivo
ISSN 0258-851X · eISSN 1791-7549 · International Institute of Anticancer Research · GREECE · Bimonthly
In Vivo: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.85; fully open access; median 34 days to acceptance (99 articles, last 24 months); community-reported acceptance: easy; 305 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
In Vivo is published by International Institute of Anticancer Research and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Inflammatory Biomarkers in Disease Prognosis, Cancer Immunotherapy and Biomarkers and Gastric Cancer Management and Outcomes, together about 19.4% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
Source: LetPub
Research area (LetPub): Medicine, Research & Experimental
Main research topics OpenAlex counts of recent articles; shares are approximate
- Inflammatory Biomarkers in Disease PrognosisMedicine7.9%
- Cancer Immunotherapy and BiomarkersMedicine6%
- Gastric Cancer Management and OutcomesMedicine5.5%
- Head and Neck Cancer StudiesMedicine5.4%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine5.3%
- Colorectal Cancer Surgical TreatmentsMedicine5%
- Nutrition and Health in AgingMedicine4.9%
- Esophageal Cancer Research and TreatmentMedicine4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.85LetPub ·
- CiteScore 2026-06
- 3.3LetPub ·
- SJR 2026-06
- 0.54LetPub ·
- SNIP 2026-06
- 0.68LetPub ·
- h-index
- 54LetPub ·
- h-index
- 56OpenAlex ·
- i10-index
- 1,056OpenAlex ·
- 2-year mean citedness
- 1.83OpenAlex ·
- Self-citation rate
- 5.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 366LetPub ·
Articles by year OpenAlex count · 3,512 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 305 | 305 | 79 |
| 2025 | 305 | 305 | 466 |
| 2024 | 393 | 393 | 1,287 |
| 2023 | 421 | 421 | 2,363 |
| 2022 | 314 | 314 | 2,328 |
| 2021 | 509 | 509 | 5,702 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
34 daysMedian, submission to acceptance · P25–P75 29 days – 44 days
- Acceptance to online
- —
- Submission to online
- —
- Sample
- 99 articles with submission and acceptance dates (738 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- International Institute of Anticancer Research
- Country or region
- GREECE
- Language
- English
- Frequency
- Bimonthly
- ISSN
- 0258-851X
- Electronic ISSN
- 1791-7549
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about In Vivo
What CAS zone is In Vivo in?
In the 2025 upgraded edition of the CAS Journal Ranking, In Vivo is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of In Vivo?
The latest impact factor listed by LetPub is 1.85; CiteScore 3.3, h-index 56.
How long does peer review take at In Vivo?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 34 days (interquartile range 29–44 days); authors report an average review time of 3–8 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index In Vivo?
According to LetPub and DOAJ records, In Vivo is indexed in SCIE and Scopus.
Is In Vivo open access, and what is the APC?
In Vivo is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .